Slide 1: Advancing today's therapies to enable healthier lives
Advancing today’s therapies to enable healthier lives Results for the year ended 31 December 2024 22nd April 2025 www.arecor.com
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Presentation Team
Presentation Team Dr Sarah Howell David Ellam Chief Executive Officer Chief Financial Officer >25 years' experience in biotech and pharma, >20 years' experience in the life science encompassing senior level commercial and industry, predominantly in the biotech and managerial roles: medical devices s
Slide 4: Building value through better patient care
Building value through better patient care Developing enhanced therapeutics that address areas of high unmet need in high value markets ArestatTM Platform Technology Diabetes & Obesity Revenue generating partnerships Proprietary Products R&D collaborations Technology Licensed partnerships partnershi
Slide 5: A broad and de-risked product portfolio and pipeline
A broad and de-risked product portfolio and pipeline Strong mix of commercial products and partners, and development products targeting large markets Current Product Area Research Preclinical Phase I Phase II Phase III Est launch market size AT278 Diabetes c.20301 Total prandial insulin Proprietary
Slide 6: Operational highlights (including post-period events)
Operational highlights (including post-period events) Focussed in areas of high met unmet patient need in high value markets Diabetes & Obesity • AT278 demonstrated superiority to NovoRapid® and Humulin® R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index (BMI) • Pos
Slide 7: Best-in-class insulin proprietary products
Best-in-class insulin proprietary products Serving unmet needs in large commercial markets
Slide 8: Catalyzing next generation automated insulin delivery (AID) system
Catalyzing next generation automated insulin delivery (AID) system Simplifying care, reducing burden and broadening access to all that would benefit from AID systems Algorithm Calculates insulin AT247 CGM dose based on Measures blood CGM reading • 100U/mL ultra-rapid acting insulin glucose levels in
Slide 9: AT278 (500U/mL) demonstrated PK superiority in T2D patients with high BMI
AT278 (500U/mL) demonstrated PK superiority in T2D patients with high BMI Confirms AT278 maintains fast and superior onset of action irrespective of diabetes type (T1D & T2D) and BMI AT278 showed superiority for onset of appearance and insulin exposure (PK) during 60 mins after dosing compared with
Slide 10: AT278 (500U/mL) demonstrated PD superiority in T2D patients with high BMI
AT278 (500U/mL) demonstrated PD superiority in T2D patients with high BMI Confirms AT278 superior blood glucose lowering profile irrespective of diabetes type (T1D & T2D) and BMI AT278 showed superiority for early insulin action with accelerated onset of glucose-lowering effect (PD) during 60 mins a
Slide 11: Desired 7-day+ wear not currently achievable for nearly all T2D's
Desired 7-day+ wear not currently achievable for nearly all T2D’s AT278 can achieve 7-day wear for nearly all T2D’s across all existing insulin pumps % IIT T2D’s in the US that cannot reach Number IIT T2D’s in the US that cannot wear time vs insulin units in reservoir reach wear time vs insulin unit
Slide 12: Desired 7-day+ wear not currently achievable for > 50% T1D's
Desired 7-day+ wear not currently achievable for > 50% T1D’s AT278 can achieve 7-day wear for all T1D’s across all existing insulin pumps % IIT T1D’s in the US that cannot reach Number IIT T1D’s in the US that cannot wear time vs insulin units in reservoir reach wear time vs insulin units in reservo
Slide 13: US Initial Addressable Market for AT278 is attractive at ~$2.9 Bn
US Initial Addressable Market for AT278 is attractive at ~$2.9 Bn Significant commercial opportunity for AT278 serving unmet patient need in a large market US Initial Addressable Market of insulin revenue alone based on two high need market segments: A: PWDs with high TDD (>100U/day), preferring pum
Slide 14: Pathway to pivotal AT278-pump Phase 2 clinical study
Pathway to pivotal AT278-pump Phase 2 clinical study End 2025 End 2026 ---------------------- ---------------------- Why is this study important: Regulatory Type C Type C • Accelerated pathway to end of Request Feedback IND Phase 2 Q2 25 H2 25 • Pivotal Phase 2 clinical data continuously dosing AT27
Slide 15: Oral Delivery of Peptides
Oral Delivery of Peptides Significant opportunity starting with oral GLP-1 Page 14 Arecor 2025
Slide 16: Significant additional upside opportunity in oral peptide delivery
Significant additional upside opportunity in oral peptide delivery Development of oral GLP and additional therapies offering alternative treatment options in large markets Oral delivery PoC GLP-1 • Initial target to develop enhanced oral GLP-1 • PoC to improve oral GLP-1 (Rybelsus®): • Enhance bioav
Slide 17: Significant deal making in oral delivery space
Significant deal making in oral delivery space Demonstrating large pharma investor interest and opportunity for Arecor to create transformational value Significant acceleration in deal-making spanning in-licensing products & technology, M&A and investment Mar 24: Metsera license rights to D&D Apr 24
Slide 18: Financials and upcoming catalysts
04 Financials and upcoming catalysts Page 17 Arecor 2025
Slide 19: 2024 Key Financials
2024 Key Financials £m 2024 2023 Future R&D expenditure to focus on areas of highest value creation Revenues 5.1 4.6 Increase in non-Ogluo products (i) proprietary diabetes portfolio and (ii) oral peptide delivery platform R&D Expenses (3.0) (5.4) Tight control on expenses continuing into 2025 SG&A
Slide 20: Investment highlights and upcoming catalysts
Investment highlights and upcoming catalysts Multiple opportunities for significant value creation • Positive strategic partnership discussions on-going with multiple potential partners to bring transformational AT278-pump product to market • Series of pre-clinical PK studies and data to optimize bi
Slide 21: Thank you
Contact Sarah Howell, CEO sarah.howell@arecor.com David Ellam, CFO david.ellam@arecor.com www.arecor.com Thank you